Sanofi has received orphan designation from the EMA for rilzabrutinib, a reversible covalent BTK inhibitor, to treat IgG4-RD.

The US-EU pharma tariff cap has been finalized at 15%, impacting manufacturing, supply chain, and quality and promoting ...

Can BTK inhibitors finally move the needle in progressive MS? Dr Robert Fox joins Dr Anne Cross to unpack the results of the ...